187 results on '"Condos, Rany"'
Search Results
2. Pulmonary Crohnʼs Disease Masquerading as Lymphoma
3. Quantitative Characterization of Respiratory Patterns on Dynamic Higher Temporal Resolution MRI to Stratify Postacute Covid‐19 Patients by Cardiopulmonary Symptom Burden
4. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry
5. Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action
6. Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) Patterns on High-Resolution Computed Tomography
7. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
8. LUNG ULTRASOUND IN THE OUTPATIENT SETTING TO ASSESS FOR POST-COVID LUNG ABNORMALITIES
9. ASSESSING DIAPHRAGMATIC FUNCTION IN PATIENTS RECOVERED FROM COVID-19
10. Respiratory care in familial dysautonomia: Systematic review and expert consensus recommendations
11. Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.
12. Low-field 0.55 T MRI for assessment of pulmonary groundglass and fibrosis-like opacities: Inter-reader and inter-modality concordance
13. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry
14. The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York
15. CT of Post-Acute Lung Complications of COVID-19
16. THE CLINICAL IMPACT OF COVID-19 ON CYSTIC FIBROSIS PATIENTS IN NEW YORK
17. HEART RATE VARIABILITY IS REDUCED 3- AND 6-MONTHS AFTER HOSPITALIZATION FOR COVID-19 INFECTION
18. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
19. Quality assurance in a large clinical trials consortium: The experience of the Tuberculosis Trials Consortium
20. Cytokine-Based Approaches to the Treatment of Multidrug-Resistant Tuberculosis
21. The Effect of Inhaled IFN- γ on the Cytokine Profile in the Alveolar Space in Idiopathic Pulmonary Fibrosis (IPF)
22. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis
23. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
24. The Burden of Exposure-Related Diffuse Lung Disease
25. Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis*
26. PULMONARY HYPERTENSION (PHTN) AND ALVEOLAR HEMORRHAGE IN PREGNANCY: A CASE OF MATERNAL PATENT DUCTUS ARTERIOSUS (PDA)
27. Regional Deposition of Aerosolized Interferon-γ in Pulmonary Tuberculosis
28. Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis
29. Hospitalizations in patients with idiopathic pulmonary fibrosis.
30. Does Diabetes Predispose to the Development of Multidrug-Resistant Tuberculosis?
31. Increased Incidence of Multidrug-Resistant Tuberculosis in Diabetic Patients on the Bellevue Chest Service, 1987 to 1997*
32. EXAMINING THE RELATIONSHIP BETWEEN SPIROMETRY AND USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERNS ON CT AMONG IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS
33. AN ANALYSIS OF USUAL INTERSTITIAL PNEUMONIA PATTERNS IN PATIENTS WITH COPD
34. Non-tuberculosis mycobacterium related bronchiectasis is associated with oral commensals in the lower airway
35. Local Immune Responses Correlate with Presentation and Outcome in Tuberculosis
36. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol
37. Amplification of DNA of Mycobacterium tuberculosis from peripheral blood of patients with pulmonary tuberculosis
38. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.
39. Evaluation of the airway microbiome in nontuberculous mycobacteria disease
40. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ
41. Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ)
42. Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis
43. Increased Production of IL-4 and IL-12p40 from Bronchoalveolar Lavage Cells Are Biomarkers of Mycobacterium tuberculosis in the Sputum
44. Delivery and Safety of Inhaled Interferon-γ in Idiopathic Pulmonary Fibrosis
45. Deposition Of Aerosolized Interferon Gamma In Idiopathic Pulmonary Fibrosis
46. Safety And Tolerability Of Long-term Treatment With Aerosolized Interferon Gamma In Idiopathic Pulmonary Fibrosis
47. Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
48. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers
49. Gene expression profiles of bronchoalveolar cells in pulmonary TB
50. Volatile biomarkers of pulmonary tuberculosis in the breath
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.